Dear Reader, We wish you a happy and prosperous New Year! In 2013, we are looking forward to further improving the content and quality of Human Vaccines & Immunotherapeutics (HV&I) . In addition to regular research paper submissions, the editorial team strives to provide a variety of solicited content including reviews, commentaries, company profiles and portraits of distinguished scientists in the field of vaccines and immunotherapeutics. In this first issue of the year, we draw your attention to four contributions related to the topic of New Targets: nicotine vaccines (reviewed by Goniewicz, p 13), plant-derived VLP vaccines (reviewed by Chen, p 26), clinical trial data of a poxvirus-vectored candidate tuberculosis vaccine (Rowland, p 50), and preclinical development of a DNA vaccine against Clostridium difficile (Jin, p 63). Furthermore, this issue features a Special Focus on Cancer. One research study looked at phenotype endothelial cell variations (heterogeneity) in the context of the development of an efficient tumor vaccine (Lokhov, p 195) . Four commentaries discuss therapeutic vaccines as an ultimate personalized therapy (Gulley, p 219), the potential of nanotechnology for developing vesicle-based cancer immunotherapy (Tian, p 222), surrogate measures of activity for cancer-targeting vaccines (Nemunaitis, p 213), and peptide vaccines for hepatocellular carcinoma (Nobuoka, p 210).
As usual, our monthly News, Policy and Profiles (NP&P) section provides you with a selection of the latest news in the field of vaccines and immunotherapeutics. As part of our NP&P track we are pleased to present the German biotech company immatics biotechnologies GmbH. The company focuses on developing advanced therapeutic vaccines that are active against cancers with a high 
